CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...

CRISPR-based gene editing holds great promise, but off-target effects remain a major concern, especially across diverse ...

Rare genetic diseases are challenging for patients and their families—made all the more overwhelming because symptoms tend to ...

Analysts have also weighed in on stock throughout the month. Recent analyst calls on the stock include: Needham analyst Gil ...

A Ph.D. graduate student in biomolecular engineering at UC Santa Cruz, with a background in computer science and mathematics, ...

Learn more about the research of Mayo Clinic's Gene Editing and Cellular Engineering Laboratory led by David (Chun-Wei) D.

A Ph.D. student in biomolecular engineering at the University of California, Santa Cruz, has built a software program ...

UC Berkeley and Caltech researchers identified a gene circuit in zebrafish that allows heart regeneration after injury. Using ...

CRISPR Therapeutics (NasdaqGM:CRSP) witnessed a substantial price movement, increasing 57% over the last quarter. This significant rise aligns with key developments, such as the company's inclusion in ...

CRISPR is revolutionizing medicine by enabling precise DNA edits, treating genetic diseases like sickle cell anemia and ...

Genome editing technologies like CRISPR-Cas9 have transformed biology, medicine, and agriculture, but concerns remain about ...